Shin-Tsung Huang

Title: Innovations by Shin-Tsung Huang in Cancer Immunotherapy

Introduction

Shin-Tsung Huang is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer immunotherapy, holding 2 patents that focus on innovative methods for treating tumors. His work is pivotal in advancing personalized medicine and improving patient outcomes.

Latest Patents

One of his latest patents is titled "Personalized cancer immunotherapy." This patent discloses a method for obtaining an antibody or antigen-binding fragment that specifically binds to a tumor sample. The process involves administering autologous dendritic cells to a subject, taking immune cells and a tumor sample from the subject, constructing an antibody library of the immune cells, and screening the library to obtain the specific antibody. This method also includes engineering immune cells and utilizing the antibody for therapeutic purposes.

Another significant patent is focused on an "Antibody specific to nectin cell adhesion molecule 4 and uses thereof." This patent describes a modified antibody that is specific for nectin-4. It outlines methods for detecting or diagnosing tumors, assessing prognosis, and a pharmaceutical composition for treating or preventing tumors in afflicted subjects.

Career Highlights

Shin-Tsung Huang is currently associated with Navi Bio-therapeutics, Inc., where he continues to innovate in the field of biotechnology. His work is characterized by a commitment to developing effective cancer treatments that leverage the body's immune system.

Collaborations

He collaborates with notable colleagues, including Bor-Yu Tsai and Wei-Ting Hsu, who contribute to his research and development efforts in cancer immunotherapy.

Conclusion

Shin-Tsung Huang's contributions to cancer immunotherapy through his innovative patents are shaping the future of personalized medicine. His work exemplifies the potential of biotechnology to transform cancer treatment and improve patient care.